Bridging from conventional marketed extended release formulations to new tamper resistant alternatives
| Autor: | H. Stahlberg, M. Brett, J. Ossig, E. Galia, B. Wenge |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Drug
medicine.medical_specialty business.industry media_common.quotation_subject Addiction Alcohol dependence Mental health Heroin Anesthesiology and Pain Medicine Neurology Research centre Medicine Neurology (clinical) business Psychiatry Extended Release Formulations media_common Buprenorphine medicine.drug |
| Zdroj: | The Journal of Pain. 13:S73 |
| ISSN: | 1526-5900 |
| Popis: | s / Drug and Alcohol Dependence 140 (2014) e169–e251 e215 Conclusions: Buprenorphine for inpatient medically-assisted opioid withdrawal has been shown to be an effective treatment strategy over the past 3 years at the Centre for Addiction andMental Health. The treatment has been used in primarily prescription opioid users, with lower success rates associated with higher daily prescription opioid use and those using heroin on a regular basis. Further research into these associations to optimize treatment success is warranted. Financial support: Centre for Addiction and Mental Health. http://dx.doi.org/10.1016/j.drugalcdep.2014.02.596 Exploring gender differences among people who inject drugs in Australia: Findings from the 2012 Illicit Drug Reporting System Jennifer Stafford, Lucy Burns National Drug and Alcohol Research Centre, Sydney |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|